Merck & Co. (MRK)
(Delayed Data from NYSE)
$125.26 USD
-0.59 (-0.47%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $125.26 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
MRK 125.26 -0.59(-0.47%)
Will MRK be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MRK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRK
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
MRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Countdown to Merck (MRK) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
Other News for MRK
Merck ups annual guidance ahead of second quarter earnings
Merck and Pfizer combination therapy recommended for European approval
Morning Brew: Keytruda Combo Therapy Endorsed by EMA, BMY's Phase 3 Win, and More
Pfizer, Merck bladder cancer therapy endorsed for approval in EU
Dividend Roundup: Wells Fargo, General Motors, Merck, Delta Air Lines, and more